New services to enable U.S. biopharmaceutical companies to accelerate development of biosimilar. Goettingen, Germany | Boston, MA, USA – November 10, 2016: Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry, opened a new bioanalytical and biosafety testing laboratory yesterday in the major biotech hub of Boston, Massachusetts. This dedicated bioanalytical laboratory More
Read our biosafety testing services brochure.
Collaborative poster with DiscoverX on the development and evaluation of novel bioassay for Denosumab activity.
Improve speed to clinic and mitigate risk with appropriate analytical analysis View webinar here.
Scientific poster on orthogonal analytics for biosimilars
Reduce risk of biosimilar development with an orthogonal approach to physicochemical and bioanalytical methods
Read our latest white paper on using orthogonal methods during biosimilar development.
Read our article on the advances in biosimilar development. Read the full magazine here. *This article is taken from European Biopharmaceutical Review October 2016, pages 12-17. © Samedan Ltd
Our Senior Technical Marketing Manager, Brian Wendelburg recently wrote an article for Laboratory news discussing how successful biosimilar mAbs have been and the challenges that remain. To read the full article, click here.
Read our cell line development brochure.
In-depth profiling of IgG glycosylation coupled with ADCC assays enables generation of robust biosimilar comparability data Glasgow, UK – July 7, 2016: Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry, announced the launched of a new Released N-Glycan Assay for the in-depth profiling of IgG glycosylation. This new physico-chemical assay, More